As clinical trials with active biologics in HS (for example, anti-TNF-α and anti-IL-17 antibodies and JAK inhibitors) and AD (for example, cytokine-targeting antibodies and JAK inhibitors) have shown improvement in skin lesions and symptoms as early as 4 weeks into treatment39–44, we explored the clinical activity of KT-474 administered to patients for 4 weeks as part of the phase 1 study. Here, IL17A is linked to Alzheimer disease.